List of Excipients in Branded Drug PYRUKYND

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	CELLULOSE, MICROCRYSTALLINE	2035-04-11
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	CROSCARMELLOSE SODIUM	2035-04-11
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	FD&C BLUE NO. 2	2035-04-11
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	HYPROMELLOSE	2035-04-11
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	LACTOSE MONOHYDRATE	2035-04-11
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	MANNITOL	2035-04-11
Agios Pharmaceuticals Inc	PYRUKYND	mitapivat	71334-205	SODIUM STEARYL FUMARATE	2035-04-11

PYRUKYND Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Pyrukynd (mitapivat) is an oral pyruvate kinase activator approved in the United States for hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited red-blood-cell disorder. Its commercial formulation is an immediate-release tablet in 5 mg, 20 mg, and 50 mg strengths. The main excipient opportunity is not a simple tablet copy. It is the development of differentiated oral products, manufacturing platforms, and global-market formulations that preserve mitapivat exposure while improving dose flexibility, swallowing, stability, and supply economics.

Agios Pharmaceuticals controls the commercial product. The FDA-approved formulation uses conventional solid-dose excipients, leaving potential opportunities in pediatric delivery, orally dispersible dosage forms, liquid formulations, modified-release systems, and manufacturing-process improvements. Regulatory and patent risks remain material because mitapivat is a small-molecule orphan drug with United States market exclusivity extending into 2029 under the orphan-drug framework. [1][2]

What is Pyrukynd and how is it formulated?

Pyrukynd contains mitapivat sulfate, a small-molecule activator of red blood cell pyruvate kinase. The tablets are administered orally and are available in three strengths:

Product strength	Dosage form	Primary commercial use
5 mg	Immediate-release tablet	Dose initiation and titration
20 mg	Immediate-release tablet	Intermediate dosing
50 mg	Immediate-release tablet	Higher maintenance dosing

The recommended starting regimen is generally 5 mg twice daily, with titration based on hemoglobin response and tolerability. The label permits titration through the available strengths, making dose proportionality, tablet identification, content uniformity, and packaging accuracy commercially important. [1]

The FDA label identifies conventional tablet and film-coating excipients. Public labeling describes excipients including mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and coating components. Exact excipient quantities and manufacturing parameters are generally not disclosed in the prescribing information. [1]

What functions do the Pyrukynd excipients perform?

The excipient system is consistent with an immediate-release, low-dose tablet:

• Mannitol can provide bulk and improve mouthfeel.
• Microcrystalline cellulose supports compressibility and tablet robustness.
• Croscarmellose sodium promotes disintegration.
• Magnesium stearate reduces friction during compression and ejection.
• Film-coating materials support appearance, identification, swallowability, and protection from handling.
• Colorants and coating opacifiers can differentiate the 5 mg, 20 mg, and 50 mg strengths.

Because the active dose is low relative to tablet mass, blend uniformity is a core manufacturing issue. A commercial generic or alternative product would need to control API segregation, lubrication sensitivity, tablet hardness, dissolution, and dose-unit uniformity.

What excipient strategy does Pyrukynd use?

Pyrukynd uses a conventional immediate-release tablet strategy rather than a technically complex delivery system. That choice has several commercial effects.

First, the product is suitable for standard oral-solid-dose manufacturing. It does not require sterile processing, specialized injectables equipment, lipid nanoparticles, or high-containment biologics infrastructure.

Second, the formulation supports dose titration. A three-strength presentation can reduce the need for tablet splitting and can simplify physician prescribing. It also creates a larger finished-product packaging footprint, because each strength requires separate manufacturing, testing, labeling, inventory, and serialization.

Third, the formulation creates an opportunity for lifecycle products. A competitor could pursue a smaller tablet, a dispersible tablet, a granule, or an oral liquid while retaining the same active pharmaceutical ingredient. Such products may have clinical value for patients with dysphagia, pediatric patients, or patients who have difficulty managing multiple strengths.

What formulation patents protect Pyrukynd?

Publicly available product labeling does not establish that the commercial excipient composition is protected by a standalone formulation patent. Mitapivat’s intellectual-property position is more likely to involve a combination of composition-of-matter, therapeutic-use, salt, formulation, and manufacturing claims.

A competitor must evaluate at least five claim categories:

Claim category	Potential relevance to an excipient strategy
Composition of matter	Can block use of mitapivat itself during the patent term
Salt or solid-state form	Can restrict use of a particular mitapivat salt or crystal form
Method of treatment	Can create infringement risk for labeled use in pyruvate kinase deficiency
Formulation	May cover dosage forms, release profiles, or excipient combinations
Manufacturing process	May limit use of a protected synthesis, crystallization, or purification step

An excipient substitution does not avoid composition-of-matter or method-of-use protection. It may help design around a narrow formulation claim, but only after claim construction, prosecution-history review, and jurisdiction-specific infringement analysis.

The Orange Book should be reviewed for current listed patents and regulatory exclusivities before any U.S. launch decision. The listing status can change through patent certifications, regulatory updates, and supplemental approvals. [3]

When does Pyrukynd lose exclusivity?

Pyrukynd received FDA approval on February 17, 2022. It received orphan-drug designation for pyruvate kinase deficiency, providing seven years of U.S. orphan-drug exclusivity for the approved indication, subject to statutory exceptions. The orphan exclusivity period therefore runs approximately to February 2029. [1][4]

The product also received five-year new chemical entity exclusivity from FDA approval. That period generally prevents submission of an abbreviated new drug application containing a Paragraph IV certification during the first four years, subject to statutory exceptions. The NCE period has expired, but orphan exclusivity and any unexpired patents can continue to affect generic entry. [1][2]

Milestone	Date or period	Commercial effect
FDA approval	February 17, 2022	Starts NCE and orphan-exclusivity analysis
NCE exclusivity	Approximately five years	Early ANDA filing restriction
Orphan exclusivity	Approximately seven years	Blocks approval of the same drug for the protected indication, subject to exceptions
Orphan exclusivity endpoint	Approximately February 2029	Potential indication-specific approval opening
Patent protection	Patent-specific	May extend beyond regulatory exclusivity

Patent expiry dates cannot be inferred solely from the approval date. Patent term adjustment, patent-term extension, terminal disclaimers, and Orange Book listings must be assessed patent by patent.

What generic entry risks exist for Pyrukynd?

The principal generic-entry pathways are conventional ANDA development, a 505(b)(2) application for a differentiated dosage form, and post-exclusivity indication-specific entry.

ANDA pathway

An ANDA sponsor would normally need to demonstrate pharmaceutical equivalence and bioequivalence to the listed product. The sponsor could use different inactive ingredients if the finished product remains pharmaceutically equivalent and meets FDA requirements. The formulation development program would focus on:

• Mitapivat assay and content uniformity
• Comparative dissolution
• Impurity and degradation control
• Tablet hardness and friability
• Stability under ICH conditions
• Bioequivalence across relevant strengths
• Color, shape, imprint, and packaging differences

A Paragraph IV certification could trigger patent litigation. A 30-month stay may delay approval if the innovator files suit within the statutory period. [5]

505(b)(2) pathway

A 505(b)(2) product could target an oral suspension, orally dispersible tablet, granule, or other dosage form that relies in part on FDA’s findings for Pyrukynd. This pathway can be commercially attractive when the product addresses a patient need that is difficult to serve with a conventional ANDA.

The applicant would still need to address listed patents and exclusivity. A new dosage form may require clinical pharmacology studies, food-effect work, dose-proportionality analysis, and stability data.

What are the best excipient opportunities for Pyrukynd?

Pediatric and dysphagia formulations

The strongest product opportunity is a swallowability-focused formulation. Pyruvate kinase deficiency is a lifelong condition, and patients may require chronic treatment. A dispersible tablet, granule, or oral suspension could improve administration for children and adults who cannot swallow conventional tablets.

Potential excipient technologies include:

• Taste-masking polymers
• Ion-exchange resins
• Mannitol-based orally disintegrating systems
• Suspending agents
• Wetting agents
• Buffer systems
• Preservative systems for multidose liquids
• Dose-metering packaging

Mitapivat’s pharmacology creates a formulation constraint: excessive binding or delayed release could alter systemic exposure. Any taste-masking system must avoid reducing bioavailability or creating dose variability.

Smaller and higher-load tablets

A formulation with improved API loading could reduce tablet size. This would require control of powder flow, compressibility, segregation, and dissolution. Direct-compression excipient systems, spray-dried composites, co-processed cellulose, and low-level superdisintegrants are potential development tools.

The commercial value is moderate for adult patients but higher for patients taking multiple medicines. A smaller tablet could also reduce packaging volume and shipping cost.

Unit-dose and adherence packaging

Pyrukynd is administered twice daily in many treatment regimens. Calendar blister packs, dose cards, and titration packs could support initiation and dose escalation. These products are primarily packaging opportunities rather than new excipient products, but they can improve adherence and reduce dispensing errors.

Titration packaging must accommodate multiple strengths and avoid mix-ups between 5 mg, 20 mg, and 50 mg tablets. Color differentiation and physical segregation are important quality controls.

Global-market formulations

Excipients permitted in the United States may not have identical acceptance status in Europe, Japan, China, or other markets. A global formulation should minimize dependence on regionally restricted colorants, preservatives, or novel excipients.

A multinational product-development strategy would favor:

• Widely accepted compendial excipients
• Low water activity
• Robust hot and humid stability
• Packaging that limits moisture ingress
• A common core formulation across markets
• Country-specific coating and labeling only where required

This approach can reduce duplicate bioequivalence and stability programs.

How strong is the commercial opportunity for excipient suppliers?

The direct excipient revenue opportunity is limited by Pyrukynd’s relatively small orphan-drug market compared with mass-market cardiovascular, metabolic, or oncology products. The strategic value is higher than the volume opportunity because an excipient supplier could use the platform in other low-dose, chronic oral medicines.

The most attractive supplier categories are:

Supplier category	Opportunity
Co-processed excipients	Improve compressibility and reduce tablet size
Taste-masking systems	Enable pediatric and dysphagia products
Oral-liquid platforms	Support 505(b)(2) development
Moisture-barrier packaging	Improve global stability
Film-coating suppliers	Strength differentiation and swallowability
Multiparticulate technologies	Enable dose flexibility
Functional lipid or polymer systems	Potentially improve exposure control, subject to pharmacokinetic validation

A supplier with a ready-to-use platform could shorten formulation development and reduce manufacturing changes. The product must still demonstrate equivalent exposure and acceptable impurity, dissolution, and stability profiles.

What licensing deals and partnerships could create value?

Potential commercial structures include:

1. An excipient supplier licenses a pediatric or dysphagia formulation platform to Agios.
2. A specialty pharmaceutical company develops a 505(b)(2) dosage form after relevant exclusivity barriers expire.
3. A generic manufacturer partners with a contract development and manufacturing organization for an ANDA.
4. A packaging company supplies titration packs, adherence systems, or moisture-protection technology.
5. A regional licensee develops country-specific formulations using a common tablet core.

A licensing transaction would likely depend on whether the partner brings a clinically differentiated dosage form, regulatory leverage, manufacturing savings, or geographic access. A basic excipient substitution is less likely to support a meaningful royalty structure unless it reduces cost, improves stability, or enables a new indication or patient population.

No public deal should be treated as evidence that a particular excipient technology is incorporated into Pyrukynd without confirmation in regulatory, patent, or transaction documents. [2]

What is the FDA regulatory status of Pyrukynd?

Pyrukynd is FDA-approved for hemolytic anemia in adults with pyruvate kinase deficiency. FDA approval was supported by clinical studies including ACTIVATE, which evaluated mitapivat in adults with pyruvate kinase deficiency. The label includes warnings and precautions relating to hemolysis after treatment interruption and reproductive risks, among other information. [1][6]

For a new excipient-based dosage form, the regulatory route depends on the product’s relationship to Pyrukynd:

• An ANDA requires pharmaceutical equivalence and bioequivalence.
• A 505(b)(2) application can rely partly on FDA’s prior findings but may require additional clinical or pharmacokinetic data.
• A supplemental NDA can support an innovator lifecycle product.
• A new pediatric formulation may require a dedicated development program and age-appropriate safety and dosing data.

An excipient that has limited prior use in an oral drug product can create FDA review risk. Novel excipients may require more extensive safety justification, which can eliminate the development advantage of an otherwise attractive formulation.

How does Pyrukynd compare with competing pyruvate kinase activator opportunities?

Mitapivat is the first approved pyruvate kinase activator. Its competitive position comes from oral administration and a disease-modifying mechanism rather than transfusion support alone. Future competition may come from additional pyruvate kinase activators, gene therapies, hematopoietic approaches, or improved supportive care.

For excipient and formulation developers, this means platform value may extend beyond Pyrukynd. A technology that improves oral delivery of mitapivat could also apply to next-generation pyruvate kinase activators, provided their physicochemical and pharmacokinetic profiles are compatible.

The key competitive variables are:

• Twice-daily dosing burden
• Dose titration complexity
• Tablet size
• Pediatric usability
• Food-effect sensitivity
• Long-term adherence
• Manufacturing cost
• Geographic availability
• Differentiation from future oral activators

What patent litigation and settlement risks affect Pyrukynd?

A generic Paragraph IV challenge could produce patent litigation involving composition, use, formulation, or process claims. A settlement could establish a licensed entry date earlier than patent expiry, subject to antitrust and regulatory considerations.

A formulation applicant should separate three risks:

1. Patent infringement risk from using mitapivat or a protected salt.
2. Regulatory delay from orphan exclusivity or a listed patent.
3. Commercial risk from launching a differentiated formulation without sufficient patient or payer demand.

An excipient change can reduce exposure to a narrow formulation claim, but it does not eliminate risk from broader claims covering mitapivat, its therapeutic use, or a protected solid form.

What manufacturing and intellectual-property barriers matter most?

The principal technical barriers are API sourcing, control of solid-state properties, blend uniformity, dissolution matching, and stability. The principal legal barriers are active-ingredient patents, use claims, formulation claims, and regulatory exclusivity.

A commercially viable competitor should prioritize:

• Independent API and salt-form characterization
• Solid-state and polymorph screening
• Design-around analysis for formulation claims
• Comparative dissolution across pH conditions
• Food-effect and bioequivalence planning
• Moisture and light stability
• Manufacturing-site qualification
• Global excipient compliance
• Packaging validation
• Orange Book and patent-register monitoring

The lowest-risk near-term strategy is usually a conventional immediate-release tablet. The highest-value strategy is a differentiated pediatric or dysphagia product, but it carries greater clinical, regulatory, and commercialization costs.

Key Takeaways

• Pyrukynd is an immediate-release mitapivat tablet available in 5 mg, 20 mg, and 50 mg strengths.
• Its excipient system is conventional and compatible with standard oral-solid-dose manufacturing.
• The strongest formulation opportunity is a pediatric, dysphagia, orally dispersible, or liquid dosage form.
• U.S. orphan-drug exclusivity runs approximately to February 2029, while patent protection must be assessed separately.
• A Paragraph IV challenge could trigger litigation and a potential 30-month approval stay.
• Excipient substitution may design around narrow formulation claims but does not avoid broader mitapivat, salt, method-of-use, or process claims.
• The largest commercial opportunity for excipient suppliers is platform reuse across rare-disease oral medicines, not Pyrukynd volume alone.
• Manufacturing economics, global excipient acceptance, moisture stability, and dose-unit uniformity are central development issues.

FAQs

Can Pyrukynd be reformulated as an oral suspension?

Yes. An oral suspension is technically feasible, but development would require control of taste, sedimentation, dose uniformity, preservative performance, chemical stability, and mitapivat exposure. A 505(b)(2) pathway may be relevant.

Are Pyrukynd’s inactive ingredients proprietary?

The broad excipient identities are disclosed in FDA labeling, but quantitative composition, processing conditions, supplier specifications, and manufacturing controls may remain confidential. Patent protection must be evaluated separately from trade-secret protection.

Would a different excipient avoid Pyrukynd patent infringement?

Not necessarily. A different excipient may avoid a narrow formulation claim, but it would not necessarily avoid patents covering mitapivat, a salt form, a therapeutic method, or a manufacturing process.

Is a pediatric Pyrukynd formulation commercially attractive?

Yes, particularly if it improves dosing accuracy and administration for children or patients with dysphagia. Commercial success would depend on pediatric demand, labeling, payer coverage, clinical development costs, and exclusivity timing.

What is the most practical generic Pyrukynd strategy?

A conventional immediate-release tablet using a different but well-established excipient system is likely the most practical route. The applicant would need to match critical quality attributes, demonstrate bioequivalence, and address listed patents and regulatory exclusivities.

References

1. U.S. Food and Drug Administration. (2022). Pyrukynd (mitapivat) prescribing information. FDA.

2. Agios Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals. FDA.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

6. Glenthøj, A., van Beers, E. J., Al-Samkari, H., et al. (2022). Mitapivat versus placebo for pyruvate kinase deficiency. New England Journal of Medicine, 386, 1432-1442.